4972422
Last Update Posted: 2021-09-05
Recruiting status is unknown
All Genders accepted | 18 Years + |
38 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase 1b Study of ZN-c3 in Chinese Subjects
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.
This study consists of Dose Escalation and Dose Expansion component in Chinese subjects with solid tumors, described briefly as follows:
Dose Escalation: Single Agent Dose Escalation of ZN-c3 in solid tumors.
Dose Expansion: Single Agent ZN-c3 in solid tumors at the RP2D dose level.
Eligibility
Relevant conditions:
Solid Tumors
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Xu Li, M.Sc
xli@zenteratx.com
+86 15902153353
Data sourced from ClinicalTrials.gov